MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fmed.2025.1737919

Медицинская библиотека · Frontiers in medicine · 2026

Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma.

Garofano Francesca, Corsale Anna Maria, Biondo Marta, Romano Andrea, Schmidt-Wolf Ingo, Gullà Anna Maria, Siragusa Sergio, Botta Cirino

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

Multiple myeloma (MM) remains incurable despite effective therapies, with most patients eventually relapsing. Chimeric antigen receptor (CAR) T-cell therapy has improved treatment options but is limited by antigen escape and lack of durable responses. To expand the spectrum of actionable antigens, we sought to identify novel CAR-T actionable targets.

METHODS

We analyzed 11 publicly available single-cell RNA sequencing datasets from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering MM (SMM), MM, relapsed/refractory MM (RRMM) and healthy donors. Plasma cell-specific surface proteins were identified via bioinformatic filtering and validated on external bulk transcriptomic database of ~2,000 patients and by flow cytometry on MM cell lines and primary bone marrow samples.

RESULTS

We identified 15 plasma cell-associated surface proteins, including BCMA, CD138, CD38, and SLAMF7. Five molecules-TNFRSF13B (TACI), CD59, FCGR2B (CD32B), SLC44A1 (CD92), and CD320-were prioritized for further study. CD320 and SLC44A1 were upregulated with disease stage and associated with poor survival, while TNFRSF13B, CD59, and FCGR2B were enriched in advanced disease and linked to better outcomes. Cytogenetic clustering linked these molecules to specific genetic backgrounds, suggesting subtyperelated expression patterns. Flow cytometry confirmed the surface expression of CD59, SLC44A1, TNFRSF13B and CD320.

DISCUSSION: CD320, SLC44A1, and TNFRSF13B are promising, clinically relevant targets for CAR T-cell therapy in MM. Their stage-specific expression and prognostic significance support their potential to enhance existing immunotherapeutic strategies.

Для цитирования: Garofano Francesca, Corsale Anna Maria, Biondo Marta, Romano Andrea, Schmidt-Wolf Ingo, Gullà Anna Maria, Siragusa Sergio, Botta Cirino. Identification of CD320, SLC44A1 and TNFRSF13B as potential novel therapeutic targets for CAR T-cell therapy in multiple myeloma.. Frontiers in medicine. 2026. DOI: 10.3389/fmed.2025.1737919.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.